‘Those of us who have studied invertebrate model organisms throughout our careers have been nervous that NIH study sections will shut the door on our funding in favor of funding studies in mammals. But my last grant application to the NIH proposing experiments in C. elegans got a perfect score! ‘
NemaMetrix Inc. is the winner of the first “Most Innovative” health startup at Demo Day organized by CBInsights.
The latest issue of Drug Discovery News (DDNews) features a special report on Animal Models of Disease, highlighting the NemaMetrix/Knudra merger and the value of C. elegans as a model organism for disease research.
Take advantage of our once a year savings. Up to 15%.
Dr. Andy Golden at NIH discusses his work on identifying regulators and interactors of conserved genes in C. elegans that, when mutated, can cause human disease and opportunities to use C. elegans as a model in clinical and translational research.